Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with ...

Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...

AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.

With AstraZeneca reported to be looking into moving its listing across the Atlantic, should investors buy the stock ahead of ...